Phase III
Eli Lilly’s ANNOUNCE Phase III clinical trial of Lartruvo (olaratumab) in advanced or metastatic soft tissue sarcoma failed to meet the primary endpoints of overall survival.
Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting the latest data from post-hoc analyses of a Phase III clinical study (REFLECT/Study 304) on its in-house discovered multiple receptor tyrosine kinase inhibitor lenvatinib mesylate will be presented during the 2019 Gastrointestinal Cancers Symposium (ASCO-GI) in San Francisco from January 17 to 19.
Merck’s Keytruda just keeps on proving its value to the company and patients. The company released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
For a moment, simply contemplate the possible price: $2.1 million for a drug. It’s not just any drug, however. Cambridge, Mass.-based bluebird bio’s LentiGlobin is a gene therapy being evaluated for transfusion-dependent ß-thalassemia.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.
Biotech and pharma companies came roaring out of the gate on the first day of the annual J.P. Morgan Healthcare Conference with big deals, expansions and promises of growth and pipeline sustainability.
UroGen Pharma, based in New York, announced positive topline results from its Phase III OLYMPUS clinical trial. The trial evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC).
Biotech entrepreneur Vivek Ramaswamy has launched another subsidiary for Roivant Sciences. Ramaswamy will provide an update on the new company, as well as other members of the Roivant family during a Monday presentation at JPM19.
CAMP-1 and CAMP-2 Phase 3 pivotal trials for molluscum contagiosum both achieve statistical significance for the primary endpoint with p-values less than 0.0001
Retrophin, Inc. announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA nephropathy, a rare kidney disorder that often leads to end-stage renal disease
PRESS RELEASES